Brief: Sonnet Biotherapeutics Early Safety Data From Co’S Phase 1B/2A Clinical Trial Of Son-080 In Cipn Met Study’S Initial Pre-Specified Objective

Sonnet Biotherapeutics Holdings

11/03/2024 12:28

March 11 (Reuters) - Sonnet Biotherapeutics Holdings Inc
 SONN.O :
    * SONNET BIOTHERAPEUTICS: EARLY SAFETY DATA FROM CO’S PHASE
1B/2A
CLINICAL TRIAL OF SON-080 IN CIPN MET STUDY’S INITIAL
PRE-SPECIFIED OBJECTIVE
    * SONNET BIOTHERAPEUTICS- ADVERSE EVENT PROFILE &
TOLERABILITY OF
SON-080 CONSISTENT WITH DATA FROM PREVIOUS IL-6 CANDIDATES
    * SONNET BIOTHERAPEUTICS- UNBLINDED SAFETY DATA FROM TWO
DOSE
LEVELS OF SON-080 COMPARED TO PLACEBO ARE EXPECTED DURING THE
SECOND HALF OF 2024

Further company coverage:  SONN.O 

 ((Reuters.Briefs@thomsonreuters.com;))